

Alessandra Tedeschi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1784427/publications.pdf>

Version: 2024-02-01

72
papers

4,807
citations

257450

24
h-index

114465

63
g-index

72
all docs

72
docs citations

72
times ranked

4105
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2015, 373, 2425-2437. | 27.0 | 1,261 |
| 2 | Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 43-56. | 10.7 | 448 |
| 3 | Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's Macroglobulinemia. <i>New England Journal of Medicine</i> , 2018, 378, 2399-2410. | 27.0 | 291 |
| 4 | A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study. <i>Blood</i> , 2020, 136, 2038-2050. | 1.4 | 281 |
| 5 | Response assessment in Waldenström macroglobulinaemia: update from the 17th International Workshop. <i>British Journal of Haematology</i> , 2013, 160, 171-176. | 2.5 | 226 |
| 6 | Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iINNOVATE): an open-label substudy of an international, multicentre, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 241-250. | 10.7 | 212 |
| 7 | Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials. <i>Haematologica</i> , 2017, 102, 1796-1805. | 3.5 | 200 |
| 8 | Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia. <i>Blood</i> , 2015, 126, 1921-1924. | 1.4 | 197 |
| 9 | Primary therapy of Waldenström macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN). <i>Blood</i> , 2013, 122, 3276-3282. | 1.4 | 180 |
| 10 | Cryoglobulinemia. <i>Blood Reviews</i> , 2007, 21, 183-200. | 5.7 | 137 |
| 11 | Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2. <i>Haematologica</i> , 2018, 103, 1502-1510. | 3.5 | 111 |
| 12 | Fludarabine plus cyclophosphamide and rituximab in Waldenström macroglobulinemia. <i>Cancer</i> , 2012, 118, 434-443. | 4.1 | 97 |
| 13 | Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia. <i>Lancet Haematology</i> , the, 2020, 7, e827-e837. | 4.6 | 96 |
| 14 | Central nervous system involvement by Waldenström macroglobulinaemia (Bing-Neel syndrome): a multi-institutional retrospective study. <i>British Journal of Haematology</i> , 2016, 172, 709-715. | 2.5 | 87 |
| 15 | Outcome of hyperleukocytic adult acute myeloid leukaemia: A single-center retrospective study and review of literature. <i>Leukemia Research</i> , 2008, 32, 1221-1227. | 0.8 | 81 |
| 16 | A sequential approach with imatinib, chemotherapy and transplant for adult Ph+ acute lymphoblastic leukemia: final results of the GIMEMA LAL 0904 study. <i>Haematologica</i> , 2016, 101, 1544-1552. | 3.5 | 72 |
| 17 | Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study. <i>Blood</i> , 2019, 133, 299-305. | 1.4 | 69 |
| 18 | Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iINNOVATE Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 52-62. | 1.6 | 62 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Invasive aspergillosis in haematological malignancies: Clinical findings and management for intensive chemotherapy completion. <i>American Journal of Hematology</i> , 2001, 68, 231-236. | 4.1 | 55 |
| 20 | Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenström's macroglobulinemia. <i>Leukemia and Lymphoma</i> , 2015, 56, 2637-2642. | 1.3 | 55 |
| 21 | Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding. <i>Hematological Oncology</i> , 2018, 36, 624-632. | 1.7 | 55 |
| 22 | First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab <i></i> versus <i></i> chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial. <i>Haematologica</i> , 2022, 107, 2108-2120. | 3.5 | 53 |
| 23 | Multicenter Total Therapy Gimema LAL 1509 Protocol for De Novo Adult Ph+ Acute Lymphoblastic Leukemia (ALL) Patients. Updated Results and Refined Genetic-Based Prognostic Stratification. <i>Blood</i> , 2015, 126, 81-81. | 1.4 | 44 |
| 24 | INCB84344-201: Ponatinib and steroids in frontline therapy for unfit patients with Ph+ acute lymphoblastic leukemia. <i>Blood Advances</i> , 2022, 6, 1742-1753. | 5.2 | 33 |
| 25 | Front-line treatment of CLL in the era of novel agents. <i>Cancer Treatment Reviews</i> , 2017, 53, 70-78. | 7.7 | 25 |
| 26 | Fludarabine, Cyclophosphamide, and Rituximab in Salvage Therapy of Waldenström's Macroglobulinemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 231-234. | 0.4 | 24 |
| 27 | Single-agent ibrutinib versus chemoimmunotherapy regimens for treatment-naïve patients with chronic lymphocytic leukemia: A cross-trial comparison of phase 3 studies. <i>American Journal of Hematology</i> , 2018, 93, 1402-1410. | 4.1 | 24 |
| 28 | A phase II multi-center trial of pentostatin plus cyclophosphamide with ofatumumab in older previously untreated chronic lymphocytic leukemia patients. <i>Haematologica</i> , 2015, 100, e501-e504. | 3.5 | 22 |
| 29 | Role of fludarabine in hematological malignancies. <i>Expert Review of Anticancer Therapy</i> , 2006, 6, 1141-1161. | 2.4 | 21 |
| 30 | WALDENSTROM'S MACROGLOBULINEMIA: AN UPDATE. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2018, 10, e2018004. | 1.3 | 21 |
| 31 | Phase 2 CAPTIVATE results of ibrutinib (ibr) plus venetoclax (ven) in first-line chronic lymphocytic leukemia (CLL). <i>Journal of Clinical Oncology</i> , 2018, 36, 7502-7502. | 1.6 | 21 |
| 32 | Lymphomas associated with chronic hepatitis C virus infection: A prospective multicenter cohort study from the Rete Ematologica Lombarda (REL) clinical network. <i>Hematological Oncology</i> , 2019, 37, 160-167. | 1.7 | 15 |
| 33 | Diagnostic framing of IgM monoclonal gammopathy: Focus on Waldenström's macroglobulinemia. <i>Hematological Oncology</i> , 2019, 37, 117-128. | 1.7 | 15 |
| 34 | Is HBV prophylaxis required during CLL treatment with ibrutinib?. <i>Leukemia and Lymphoma</i> , 2017, 58, 2966-2968. | 1.3 | 14 |
| 35 | Do age, fitness and concomitant medications influence management and outcomes of CLL patients treated with ibrutinib?. <i>Blood Advances</i> , 2021, , . | 5.2 | 14 |
| 36 | High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study. <i>Cancer Chemotherapy and Pharmacology</i> , 2007, 59, 771-779. | 2.3 | 13 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Fludarabine-Based Combination Therapies for Waldenström's Macroglobulinemia. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, 67-70. | 1.4 | 13 |
| 38 | THERAPY-RELATED MYELOID NEOPLASMS IN CHRONIC LYMPHOCYTIC LEUKEMIA AND WALDENSTROM MICROGLOBULINEMIA. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2011, 3, e2011031. | 1.3 | 13 |
| 39 | A scoring system to predict the risk of atrial fibrillation in chronic lymphocytic leukemia. <i>Hematological Oncology</i> , 2019, 37, 508-512. | 1.7 | 13 |
| 40 | Autoimmune Hemolytic Anemia and Immune Mediated Thrombocytopenia in the Phase III RESONATE™ Study of Ibrutinib Vs Ofatumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Including a Case Report. <i>Blood</i> , 2014, 124, 5654-5654. | 1.4 | 13 |
| 41 | Pattern of Care in Indolent Non Follicular Lymphoma: A Report from NF10 Project, an International, Prospective, Observational Study Coordinated By the Fondazione Italiana Linfomi. <i>Blood</i> , 2015, 126, 2686-2686. | 1.4 | 12 |
| 42 | Consensus Statement on the Management of Waldenström Macroglobulinemia Patients During the COVID-19 Pandemic. <i>HemaSphere</i> , 2020, 4, e433. | 2.7 | 11 |
| 43 | Bing Neel Syndrome in a Previously Untreated Patient With Waldenström's Macroglobulinemia: Contribution of MYD88 L265P Mutation on Cerebrospinal Fluid. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, e7-e9. | 0.4 | 10 |
| 44 | Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study. <i>Annals of Hematology</i> , 2021, 100, 1733-1742. | 1.8 | 10 |
| 45 | Ibrutinib provides favourable survival outcomes in patients with comorbidities <i>versus</i> established therapies. <i>British Journal of Haematology</i> , 2019, 186, 175-180. | 2.5 | 9 |
| 46 | From Biology to Treatment of Monoclonal Gammopathies of Neurological Significance. <i>Cancers</i> , 2022, 14, 1562. | 3.7 | 9 |
| 47 | Long-Term Follow-up of Ibrutinib Treatment for Rituximab-Refractory Waldenström's Macroglobulinemia: Final Analysis of the Open-Label Substudy of the Phase 3 iNNOVATE™ Trial. <i>Blood</i> , 2020, 136, 38-39. | 1.4 | 7 |
| 48 | Fludarabine, Cyclophosphamide and Rituximab in Waldenström's Macroglobulinemia: An Effective Regimen Requiring a New Category of Response Criteria and a Delayed Assessment of Results. <i>Blood</i> , 2007, 110, 1290-1290. | 1.4 | 7 |
| 49 | The spectrum of use of rituximab in chronic lymphocytic leukemia. <i>OncoTargets and Therapy</i> , 2010, 3, 227. | 2.0 | 6 |
| 50 | A cross-trial comparison of single-agent ibrutinib versus chlorambucil-obinutuzumab in previously untreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. <i>Haematologica</i> , 2020, 105, e164-e168. | 3.5 | 5 |
| 51 | Bendamustine and subcutaneous alemtuzumab combination is an effective treatment in relapsed/refractory chronic lymphocytic leukemia patients. <i>Haematologica</i> , 2014, 99, e159-e161. | 3.5 | 4 |
| 52 | Health-related quality of life in Waldenström Macroglobulinemia and IgM-related disorders: A single institution experience. <i>Hematological Oncology</i> , 2020, 38, 111-113. | 1.7 | 4 |
| 53 | Updated results of the ASPEN trial from a cohort of patients with <i>MYD88</i> wild-type (<i>MYD88</i> ^{WT}) Waldenström macroglobulinemia (WM).. <i>Journal of Clinical Oncology</i> , 2020, 38, e20056-e20056. | 1.6 | 4 |
| 54 | Use of BTK inhibitors with focus on ibrutinib in mantle cell lymphoma: An expert panel opinion statement. <i>Hematological Oncology</i> , 2022, 40, 518-527. | 1.7 | 4 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Ibrutinib for the treatment of chronic lymphocytic leukemia. <i>Expert Review of Hematology</i> , 2019, 12, 273-284. | 2.2 | 3 |
| 56 | What is Fitness in the Era of Targeted Agents?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, S84-S86. | 0.4 | 3 |
| 57 | Outcome of Transformed Marginal Zone Lymphomas Treated in the Rituximab Era. <i>Blood</i> , 2015, 126, 5098-5098. | 1.4 | 3 |
| 58 | Use of BTK inhibitors with special focus on ibrutinib in Waldenström macroglobulinemia: An expert panel opinion statement. <i>Hematological Oncology</i> , 2022, 40, 332-340. | 1.7 | 3 |
| 59 | Clinical utility and patient considerations in the use of ofatumumab in chronic lymphocytic leukemia. <i>Biologics: Targets and Therapy</i> , 2015, 9, 75. | 3.2 | 2 |
| 60 | Ofatumumab plus chlorambucil as a first-line therapy in less fit patients with chronic lymphocytic leukemia: analysis of COMPLEMENT1 and other monoclonal antibodies association data. <i>Therapeutic Advances in Hematology</i> , 2016, 7, 222-230. | 2.5 | 2 |
| 61 | Long-Term Toxicity of Therapy in Waldenström Macroglobulinemia. , 2017, , 357-365. | | 1 |
| 62 | Positive Direct Antiglobulin Test (DAT) in Chronic Lymphocytic Leukemia (CLL) Patients: Correlation with Prognostic Factors.. <i>Blood</i> , 2009, 114, 2351-2351. | 1.4 | 1 |
| 63 | Results of a Phase II Multicenter Study of Immunochemotherapy with Fludarabine, Cyclophosphamide and Rituximab (FCR) for Symptomatic Waldenström's Macroglobulinemia. <i>Blood</i> , 2008, 112, 3692-3692. | 1.4 | 1 |
| 64 | Clinical and Biological Implications of Hepatitis C Virus Positivity in Waldenström's Macroglobulinemia Patients.. <i>Blood</i> , 2009, 114, 2934-2934. | 1.4 | 1 |
| 65 | Ibrutinib dose intensity in high-risk chronic lymphocytic leukemia. <i>Hematological Oncology</i> , 2022, 40, 1100-1104. | 1.7 | 1 |
| 66 | Overview on clinical trials in Waldenström's macroglobulinemia. <i>Clinical Investigation</i> , 2014, 4, 1139-1154. | 0.0 | 0 |
| 67 | Fludarabine, Cyclophosphamide, and Alemtuzumab (FCC) In Relapsed/Refractory Patients with B-Cell Chronic Lymphocytic Leukemia (CLL): Final Report of the Italian Study. <i>Blood</i> , 2010, 116, 1384-1384. | 1.4 | 0 |
| 68 | Comparison Between FISH and Immunostimulatory Oligonucleotide-Induced Metaphase Cytogenetics in Previously Untreated CLL: Impact on Prognosis. <i>Blood</i> , 2011, 118, 4587-4587. | 1.4 | 0 |
| 69 | NF10 Project: An International, Prospective, Observational Study Of Patients With Indolent Non-Follicular Lymphoma. Analysis Of First 215 Patients. <i>Blood</i> , 2013, 122, 1782-1782. | 1.4 | 0 |
| 70 | Long Term Toxicity and Follow-up of Waldenström's Macroglobulinemia Patients after Salvage Treatment with Fludarabine Cyclophosphamide Rituximab or Bendamustine and Rituximab. <i>Blood</i> , 2015, 126, 3958-3958. | 1.4 | 0 |
| 71 | Efficacy and Toxicity of Nucleoside Analogs in Patients with Hairy Cell Leukemia Treated Outside Clinical Trials. <i>Blood</i> , 2015, 126, 5084-5084. | 1.4 | 0 |
| 72 | Anatomical heterogeneity of residual disease in chronic lymphocytic leukemia treated with ibrutinib. <i>Hematological Oncology</i> , 2022, 40, 1105-1108. | 1.7 | 0 |